Skip to main content
. Author manuscript; available in PMC: 2013 Jun 24.
Published in final edited form as: Biochem Pharmacol. 2010 Jul 6;80(9):1309–1316. doi: 10.1016/j.bcp.2010.06.048

Figure 1. Effect of curcumin and EF24 on A549 lung cancer cell viability.

Figure 1

(A) Structures of curcumin and the novel fluorinated curcumin analog, EF24. (B) A549 cells were grown in a 96 well plate and treated with EF24 (0.4 µM or 0.8 µM) or curcumin (10 µM) for indicated times. Cell viability was assessed by the SRB method and is expressed as percentage of vehicle-treated control (0.5% DMSO) (n = 3). The error bars indicate the standard deviation of the mean. (C) A549 cells were treated with EF24 or curcumin for 30 min before the status of ERK, p38, and JNK were determined using phospho-specific antibodies for the Thr/Tyr activation motifs.